TCIM
GEVA

TIAA CREF Investment Management’s SYNAGEVA BIOPHARMA CORP COM STK (DE) GEVA Stock Holding History

TIAA CREF Investment Management’s Portfolio GEVA Stock Details GEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-79,147
Closed -$7.72M – 3246
2015
Q1 		$7.72M Buy
79,147
+3,947
+5% +$418K 0.01% 1329
2014
Q4 		$6.98M Sell
75,200
-7,827
-9% -$618K ﹤0.01% 1390
2014
Q3 		$5.71M Sell
83,027
-4,762
-5% -$341K ﹤0.01% 1510
2014
Q2 		$9.2M Buy
87,789
+6,858
+8% +$583K 0.01% 1218
2014
Q1 		$6.71M Sell
80,931
-1,390
-2% -$129K ﹤0.01% 1404
2013
Q4 		$5.33M Buy
82,321
+6,531
+9% +$388K ﹤0.01% 1598
2013
Q3 		$4.8M Buy
75,790
+537
+0.7% +$26.4K ﹤0.01% 1610
2013
Q2 		$3.16M Buy
+75,253
New +$3.43M ﹤0.01% 1862

TIAA CREF Investment Management's GEVA Position: Q2 2015 in Review

TIAA CREF Investment Management sold out of SYNAGEVA BIOPHARMA CORP COM STK (DE) (GEVA) in Q2 2015, closing a stake of 79,147 shares — an estimated $7.72M sold.

TIAA CREF Investment Management first reported a position in GEVA in Q2 2013 and held it in 8 quarters. The position peaked at $9.2M in Q2 2014. 0 funds tracked by Wall St. Rank hold GEVA as of Q2 2015.

  • TIAA CREF Investment Management reported no remaining SYNAGEVA BIOPHARMA CORP COM STK (DE) position as of Q2 2015 after selling out during the quarter.
  • TIAA CREF Investment Management sold 79,147 SYNAGEVA BIOPHARMA CORP COM STK (DE) shares in Q2 2015, an estimated $7.72M.
  • TIAA CREF Investment Management first reported a position in SYNAGEVA BIOPHARMA CORP COM STK (DE) in Q2 2013 and held it in 8 quarters.
  • TIAA CREF Investment Management's SYNAGEVA BIOPHARMA CORP COM STK (DE) position peaked at $9.2M in Q2 2014.
  • 0 funds tracked by Wall St. Rank held SYNAGEVA BIOPHARMA CORP COM STK (DE) as of Q2 2015.

Based on TIAA CREF Investment Management's 13F filing for Q2 2015, filed 10 Aug 2015.